Respiratory

Five things for pharma marketers to know: Friday, April 21, 2017

Five things for pharma marketers to know: Friday, April 21, 2017

By

Teva launches branded competitor to GSK's Advair; Valeant prices psoriasis drug at $3,500 per month; overseas drug importation would save money, op-ed argues

David Van Sickle, Propeller Health

David Van Sickle, Propeller Health

David Van Sickle is CEO and co-founder of Propeller Health.

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

Drugmakers target severe asthma patients with biologics, but payers raise pricing issue

By

Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices

Novartis aims to bring first oral asthma drug to market in two decades

Novartis aims to bring first oral asthma drug to market in two decades

By

An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.

Top 25 respiratory brands, by sales

Top 25 respiratory brands, by sales

While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.

Why Philips' Erik Hollander turned to reinvention

Why Philips' Erik Hollander turned to reinvention

By

He describes his current charge as "transforming a more creative occupation into a science."

GSK prepares for Advair competition

GSK prepares for Advair competition

By

If generic versions by Mylan, Hikma, and Vectura are approved mid-year, GSK expects sales of Advair to be flat or decline.

BreathResearch's Nirinjan Yee on being a female entrepreneur

BreathResearch's Nirinjan Yee on being a female entrepreneur

By

A bout with Lyme disease led Yee to found a company that helps patients measure and track their breathing patterns.

GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials

GSK and Propeller Health's smart inhaler aims to improve adherence in clinical trials

By

The drugmaker is using Propeller Health's sensor technology to find new ways to improve adherence in clinical studies.

Philips takes the pharma Grand Prix at Cannes

Philips takes the pharma Grand Prix at Cannes

By

Ogilvy & Mather London developed the campaign, called Breathless Choir and set to Sting's "Every Breath You Take."

Drugmakers move to counteract expiring patents with new respiratory drugs

Drugmakers move to counteract expiring patents with new respiratory drugs

By

Symptom-driven care is falling out of fa­vor with lung-drug leaders increasingly interested in assigning optimal treatment approaches to patient conditions.

Corbus bets on cystic-fibrosis market with Resunab

Corbus bets on cystic-fibrosis market with Resunab

By

Current treatments, including steroids and ibuprofen, help control symptoms. But the side-effect profiles are difficult for patients to manage.

Top 25 respiratory products, 2014-2015

Top 25 respiratory products, 2014-2015

GlaxoSmithKline's Advair brought in $4.8 billion in U.S. sales in 2015, edging out Boehringer Ingelheim's Spiriva Handihaler ($3.4 billion) and AstraZeneca's Symbicort ($2.6 billion).

Five things for pharma marketers to know: Friday, September 25, 2015

Five things for pharma marketers to know: Friday, September 25, 2015

By

Teva acquires sensor-based inhaler; EU conditionally approves Amgen's cancer drug, Blincyto; Novartis CEO says targeted therapies may reduce unnecessary US healthcare spending

GSK asthma medication to go before FDA panel Thursday

GSK asthma medication to go before FDA panel Thursday

By

There has been little talk about mepolizumab but an approval would fill out GSK's flagging respiratory category.

Five things for pharma marketers to know: Thursday, May 21

Five things for pharma marketers to know: Thursday, May 21

By

CVS will buy institutional pharmacy Omnicare in a $12.7-billion deal; ProPublica says the FDA and GlaxoSmithKline failed to protect patients from misusing Advair; Regeneron and Sanofi expect to file RA drug sarilumab with the FDA in the fourth quarter of this year

Five things for pharma marketers to know: Thursday, May 7

Five things for pharma marketers to know: Thursday, May 7

By

A court halted the launch of Sandoz's biosimilar; GSK said it is concerned about Advair competition in the US; an FDA panel is expected to vote on a female sexual disorder drug

Five things for pharma marketers to know: Friday, May 1

Five things for pharma marketers to know: Friday, May 1

By

Nexium tops the list of Medicare's spending on brand drugs; Gilead Sciences doubles its first-quarter profit; Pfizer reportedly wants to buy a rare-disease drug company

GSK shrinks, and respiratory looks set to stumble

GSK shrinks, and respiratory looks set to stumble

By

Doctors tell investment firm Leerink they don't anticipate upping their prescriptions of the new Ellipta line.

GSK restructures, as respiratory disappoints

GSK restructures, as respiratory disappoints

By

GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.

Five things for pharma marketers to know: Friday, September 19

Five things for pharma marketers to know: Friday, September 19

By

Lilly's weekly GLP-1 shot is approved, BI expands its lung-cancer portfolio, GSK's China investigation closes, NY proposed Sovaldi triage and India imposed price limits on 36 new medicines.

BI Spiriva combo has Phase-III success

BI Spiriva combo has Phase-III success

By

The company said in a statement that the findings indicated the Spiriva-Striverdi combination treatment could help patients "return to a more independent life."

Pfizer, Novartis ink respiratory deal

Pfizer will sell two Novartis drugs in the UK.

Roche spends $8.3B for lung drug

Roche spends $8.3B for lung drug

By

Roche has beat out rumored competitors GlaxoSmithKline and Sanofi in a run-off to acquire California biotech InterMune.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

By

The FDA has approved Arnuity Ellipta for asthma.

GSK relaunches COPD.com

GSK relaunches COPD.com

By

The refresh launched soon after the company encouraged investors to take a long view of GSK as the firm posted weak respiratory numbers.

 Five things for pharma marketers to know: Friday, August 15

Five things for pharma marketers to know: Friday, August 15

By

UK drug-cost watchdog backs Sovaldi, Achillion touts HCV interim results, Avastin's latest cancer indication, Ebola outbreak worsens, COPD drug gets panel nod, and study links quick reviews and black-box warnings.

Endorsement could boost Pfizer vax

Endorsement could boost Pfizer vax

By

It could also eat into Merck's Pneumovax sales.

InterMune joins M&A fray

GlaxoSmithKline, Actelion, Sanofi and Roche are said to be among a host of suitors.

Scotland's NICE dislikes GSK's Anoro

The Scottish Medicines Consortium gave a thumb's down to GSK's drug and a Boehringer COPD drug.